₹1,210 crore as against
₹1,250 crore in the year-ago period. Meanwhile, its net sales are also likely to rise 1.5% to
₹6,870 crore vs
₹6,770 crore in the same period last year. As per the brokerage, the firm’s US sales are expected to grow 4% YoY to $384 million due to steady traction in existing products and continued price erosion. Watch out for updates on filings, approvals, and launches in China. Also, India revenue is likely to grow 6% YoY; strong traction in respiratory is to be offset by a double-digit decline in cardiac therapy. Watch out for key approvals and launches in NA over the next 12-15 months, MOSL said.” title =”Dr Reddy’s: The pharma firm is likely to post a 7.6% fall in its Q3 net profit at
₹1,210 crore as against
₹1,250 crore in the year-ago period. Meanwhile, its net sales are also likely to rise 1.5% to
₹6,870 crore vs
₹6,770 crore in the same period last year. As per the brokerage, the firm’s US sales are expected to grow 4% YoY to $384 million due to steady traction in existing products and continued price erosion. Watch out for updates on filings, approvals, and launches in China. Also, India revenue is likely to grow 6% YoY; strong traction in respiratory is to be offset by a double-digit decline in cardiac therapy. Watch out for key approvals and launches in NA over the next 12-15 months, MOSL said.”>
